anonymous
Guest
anonymous
Guest
Remember this thread. This drug will flop and it’s already over.
Celgene heads at all levels will be cut
Celgene heads at all levels will be cut
Remember this thread. This drug will flop and it’s already over.
Celgene heads at all levels will be cut
I’m interviewing for one of the sales openings, can you please be a little more specific why its going to flop and how reimbursement is giving away? Having some doubts now.
TRUTHNot many Celgene heads to cut. On the other hand, bloated BMS could cut hundreds of heads and no one would notice, especially the customers.
The launch is a dumpster fire. Drug will find its place but tell someone that will be 2 years from now.
it’s not a game changer and Covid took the selling and stealing from competition share out of the equation. So let’s sit back and watch the shit show of bad ideas over the next 18 months.
because this party is over before it started
BMS has no idea what they are doing. Covid has fucked the market up and most offices are not even letting us in to have a conversation. Most are doing tele health and are reluctant to switch a new patient unless they are having a major flare or episode. Our data isn’t that impressive (another S1P oh gee) and frankly the reimbursement debacle should have been predicted. Free drug only gets you so far and government patients are just shit out of luck. The government patients are increasing due to sky high unemployment and we have no answer for them........PAP is a joke. I’m coasting through this until hiring starts up again and then i swear I’m out of here for the first decent offer i get